Clopidogrel does not affect the pharmacokinetics of theophylline

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 2, 1999, Pages 65-68

  Caplain, Henri ^a   Thebault, Jean Jacques ^a   Necciari, José ^b  

^a Hopital de la Fondation Cognacq Jay   (France)

^b SANOFI   (France)

Author keywords

Clopidogrel; Pharmacokinetic interaction; Theophylline

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; CLOPIDOGREL; DRUG METABOLITE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLEEDING TIME; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THEOPHYLLINE BLOOD LEVEL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; MALE; MICROSOMES, LIVER; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THEOPHYLLINE; TICLOPIDINE;

EID: 0032770852     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Rall TW. Drugs used in the treatment of asthma - The methylxanthines, cromolyn sodium, and other agents. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics, 8th edition, New York: Pergamon Press, 1990: 618-637
2. Colli A, Buccino G, Cocciolo M, et al. et al. Ticlopidine-theophylline interaction. Clin Pharmacol Ther 1987;41:358-362
3. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharm 1992;44:527-532
4. Herbert JM, Frehel D, Vallee E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11:180-198
5. Combalbert J, Savi P, Rouchon MC, et al. Influence of hepatic cytochrome P450 subfamilies induction on antiaggregating activity and microsomal hepatic metabolism of the thienopyridine clopidogrel SR25990C. XIIIth European Workshop of Drug Metabolism, Bergamo, Italy, 21-25 September 1992
6. Pierce CH, Houle JM, Kieffer G, Dickinson JP. Absence of effect of clopidogrel on human hepatic P-450 activities. XVIIIth Congress of the European Society of Cardiology. Birmingham, United Kingdom. Eur Heart J 1996;17:160(Abst)
7. Internal Sanofi Report 2680/RS0097961114/02
8. Thebault JJ, Kieffer G, Lowe GDO, Nimmo WS, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost: 1999;25(Suppl 2):9-14
9. Boneu B. Clopidogrel dose-ranging phase II study in subjects with atherosclerotic disease. J Am Coll Cardiol 1996;27 2(Suppl A):132A-133A